Overview

CYC065 CDK Inhibitor and Venetoclax Study in Relapsed/Refractory CLL

Status:
Unknown status
Trial end date:
2020-05-15
Target enrollment:
Participant gender:
Summary
A Phase I Combination Study of CYC065 and Venetoclax for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
Phase:
Phase 1
Details
Lead Sponsor:
Cyclacel Pharmaceuticals, Inc.
Collaborator:
M.D. Anderson Cancer Center
Treatments:
Venetoclax